2024 organic pro forma sales growth of 8%, with pro forma adjusted EBITDA margin of 36.1%.
2025 outlook of 5-8% organic pro forma sales growth and 37-38% adjusted EBITDA margin.
2024 organic pro forma sales growth of 8% (Q4: 7%) and 8% on IFRS reported basis (Q4 7%). Food & Health Biosolutions at 7%,
and Planetary Health Biosolutions at 9%.2024 pro forma adjusted EBITDA margin of 36.1% (2H 36.8%), with 35.2% for Food & Health Biosolutions and 36.8% for Planetary Health Biosolutions. 2024 adjusted EBITDA margin on IFRS reported base of 36.2% (2H 36.8%).2024 pro forma cash flow from operating activities at EUR 1,032.5 million, including the positive one-off item in H1.2024 contribution from cost synergies at ~1pp on pro forma adjusted EBITDA margin at an 80% run rate of the 3-year EUR 80-90m target.Net debt/EBITDA at 1.4x year-end 2024 compared to 1.2x year-end 2023.Proposed dividend of DKK 4.20/share (EUR 0.56) with the total pay-out for the year unchanged compared to previous year.45 new innovations launched during the year.EUR 100m share buyback program announced for 2025.2025 outlook of 5-8% (6-9% excluding the exit from certain countries) pro forma organic sales growth and 37-38% adjusted EBITDA margin.
Ester Baiget, President & CEO: “2024 was an excellent year where we executed strongly across the business, while at the same time integrating two extraordinary companies and becoming Novonesis. I am very pleased with the overall performance in both sales and earnings, where we clearly deliver from the strength of our well-diversified portfolio of sustainable biosolutions. We address and leverage opportunities as they arise across industries and markets, enabling a strong 8% organic sales growth and 36.1% adjusted EBITDA margin for the year. Despite global instability, Novonesis is in a strong position to continue to drive attractive organic sales growth and margin expansion, also
